New Antifungal Drugs, New Approaches and Vaccines

A Study of the Effects of Increasing Doses of a Drug for the Treatment of Nail Fungus

Phase 1

16 November 2009

Efficacy and Safety Study of 4 Dose Regimens of Oral Albaconazole in Subjects With Distal Subungual Onychomycosis

Phase 2

4 August 2008

A Study to Compare the Blood Levels of Albaconazole in Healthy Subjects Who Have Received a Single Dose of 400 mg Albaconazole as a Tablet Versus Albaconazole as a Capsule

Phase 1

23 December 2009

FDA Grants Vical Orphan Drug Designation for VL-2397 for the Treatment of Invasive Aspergillosis

6 January 2016

Vical to Present Preclinical Data at ICAAC 2015 Meeting for Its Novel Antifungal Drug Candidate VL-2397

15 September 2015

FDA Grants Qualified Infectious Disease Product (QIDP) Designation to VL-2397, Vical’s Antifungal Product Candidate

19 August 2015

Vical in-licenses novel antifungal ASP2397 from Astellas Pharma

25 March 2015

MethylGene Reports Results of Phase II Trial of MGCD290

18 March 2013

METHYLGENE PRESENTS MGCD290 DATA AT THE 2012 ANNUAL INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (ICAAC)

11 September 2012

MYG MethylGene receives FDA approval for MGCD290 phase 2

18 October 2011